Kalaris Therapeutics to Present at Noble Capital Markets Emerging Growth Equity Conference

Kalaris Therapeutics Inc. will present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference on December 3, 2025. Chief Medical Officer Matthew Feinsod will speak from 11:30 to 11:55 am ET at Florida Atlantic University in Boca Raton, FL. Kalaris management will also be available for one-on-one meetings during the conference.

Kalaris Therapeutics Reports Q3 2025 Financial Progress

Kalaris Therapeutics reported Q3 2025 financial progress, highlighting significant clinical trial advancements and corporate developments. The company is set to release initial data from its Phase 1a trial by end-2025 and has begun Phase 1b/2 trial enrollment. Financially, cash reserves increased to $77 million, funding operations into 2027, with a net loss of $11.9 million, improved from last year's $38.1 million loss. The company focuses on advancing its TH103 biologic for retinal diseases, aiming to address unmet medical needs.

Kalaris Therapeutics (NASDAQ:KLRS) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Kalaris Therapeutics (NASDAQ:KLRS) reported a quarterly EPS of ($0.64), surpassing analysts' expectations of ($0.66) by $0.02. The stock decreased by $0.21 to $4.86 with a trading volume of 39,043 shares. Institutional investors own 66.05% of the stock. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and an average price target of $11.50.

Kalaris Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

Positive Outlook for Kalaris Therapeutics: Buy Rating Affirmed Amid Promising Clinical Developments

William Blair analyst Lachlan Hanbury Brown has affirmed a Buy rating for Kalaris Therapeutics (KLRS) on November 3, citing promising clinical developments. The company is progressing with its Phase I study of TH103 for neovascular age-related macular degeneration, with top-line data expected in Q4 2025. Kalaris has also started a Phase Ib/II trial and partnered with KBI Biopharma for clinical supply. Citizens JMP also initiated coverage with a Buy rating and a $20 price target, indicating a positive outlook for the company.